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Abstract
Background: The control of lymphatic filariasis (LF) caused by Wuchereria bancrofti in the Central African Region
has been hampered by the presence of Loa loa due to severe adverse events that arise in the treatment with
ivermectin. The immunochromatographic test (ICT) cards used for mapping LF demonstrated cross-reactivity with L.
loa and posed the problem of delineating the LF map. To verify LF endemicity in forest areas of Cameroon where
mass drug administration (MDA) has not been ongoing, we used the recently developed strategy that combined
serology, microscopy and molecular techniques.
Methods: This study was carried out in 124 communities in 31 health districts (HDs) where L. loa is present. At least
125 persons per site were screened. Diurnal blood samples were investigated for circulating filarial antigen (CFA) by
FTS and for L. loa microfilariae (mf) using TBF. FTS positive individuals were further subjected to night blood
collection for detecting W. bancrofti. qPCR was used to detect DNA of the parasites.
Results: Overall, 14,446 individuals took part in this study, 233 participants tested positive with FTS in 29 HDs, with
positivity rates ranging from 0.0 to 8.2%. No W. bancrofti mf was found in the night blood of any individuals but L.
loa mf were found in both day and night blood of participants who were FTS positive. Also, qPCR revealed that no
W. bancrofti but L.loa DNA was found with dry bloodspot. Positive FTS results were strongly associated with high L.
loa mf load. Similarly, a strong positive association was observed between FTS positivity and L loa prevalence.
Conclusions: Using a combination of parasitological and molecular tools, we were unable to find evidence of W.
bancrofti presence in the 31 HDs, but L. loa instead. Therefore, LF is not endemic and LF MDA is not required in
these districts.
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Background
Lymphatic filariasis (LF) is a chronic, debilitating vector-
borne disease caused by the filarial parasites Wuchereria
bancrofti, Brugia malayi and B. timori. It is transmitted
by Culex, Anopheles and Mansonia mosquitoes respect-
ively [1]. In 1997, the World Health Organization
(WHO) targeted LF for elimination by 2020 through a
strategy of mass drug administration (MDA) [2, 3]. By
the year 2000, WHO reported that, nearly 1.4 billion
people in 73 countries worldwide were at risk of LF,
with an estimated number of 120 million people in-
fected, and about 40 million people disfigured and inca-
pacitated by the disease [4]. Based on recent WHO
reports [5], LF elimination as a public health problem
was validated in several countries and 893 million people
in 49 countries worldwide remain threatened by lymph-
atic filariasis and require preventive chemotherapy.
In order to carry out MDA, LF must be mapped to de-
lineate areas where MDA is required and preventive
chemotherapy (PC) given to the eligible population (in
areas where prevalence of antigenemia is ≥1%), and with
a minimum therapeutic coverage of 65% for 5–6 years
[6]. The global strategy is a yearly single dose of two-
drugs regiment, distributed to at-risk populations In Af-
rica, WHO recommends an annual dose of ivermectin
(150 μg/kg body weight) combined with albendazole
(400 mg) due to the co-endemicity of LF and onchocer-
ciasis in this continent [7].
LF was previously mapped in Cameroon using two
strategies in two different zones. In the northern zone
(two regions), which were not endemic for loiasis, W.
bancrofti microfilaremia was confirmed microscopically
using night blood smears [2]. In the southern part (8 re-
gions) endemic for loiasis, LF was mapped based on the
positivity of the immunochromatographic test (ICT) [8].
A total of 158 health districts in Cameroon were previ-
ously identified as endemic for LF. About 134 HDs were
eligible for LF MDA following completion of epidemio-
logical mapping and based on historical data [2, 8]. The
other 24 health districts not eligible for MDA were later
on carved out into 31 health districts by the health au-
thorities and they were highly endemic for loiasis.
The implementation of MDA against LF in Cameroon
started in 2008 in the North and Far North regions [9].
However, the implementation of MDA in the southern
parts of Cameroon is facing serious drawbacks due to
the co-endemicity of Loa loa and the risk of severe ad-
verse events (SAE) in individuals with high microfilaria
(Mf) loads, if treated with ivermectin [10, 11]. In the
past, epidemiological mapping used ICT cards to assess
the prevalence of LF but recent findings in Democratic
Republic of the Congo (DRC) and Cameroon reported
cross reactivity of this tool with high L loa Mf load in
blood [12–14]. Another study demonstrated the loss of
sensitivity of the ICT test in detecting W. bancrofti in
low prevalence settings [15, 16]. Recently, a new strategy
was developed to assess LF in co-endemic areas with
other filariae [17].
To verify LF endemicity in forested areas in Cameroon
where mass drug administration has not been started,
this new strategy was applied using a combination of




The study was carried out in 31 health districts, located
in 4 Regions in the forest zone of Cameroon. Thirteen
health districts were surveyed in the East, 10 health dis-
tricts were in the Center Region, four health districts
each were in the South and Littoral Regions respectively.
A total of 124 communities were involved, 4 from each
of the 31 health districts. (Fig. 1; Supplementary material
Figures S1 and S2). These communities are located in
the forest area of Cameroon which are breeding sites of
different filarial transmitting vectors and MDA has not
been introduced in these communities. The survey was
conducted from July 2016 to January 2017.
Study design
This study was a cross-sectional community-based survey.
Following mass sensitization on the importance of the
study, a complete census of all households was carried out
in each community and 50 households selected using sim-
ple random sampling. A minimum of 2 participants were
randomly selected from each of the selected households.
In each community, at least 125 participants both male
and female of greater than 5 years, who had been resident
in the community for at least 5 years, were recruited and
screened during the day for the presence of W. bancrofti
using the Alere Filarial Test strip (FTS, Alere, Scarbor-
ough, ME, USA). All eligible participants in the commu-
nity who willingly consented or accented (if below 21
years) were recruited for the study. Sociodemographic fac-
tors were collected using a structured questionnaire. We
used the algorithm shown in Fig. 2 to detect the presence
ofW. bancrofti. Blood samples for FTS testing, thick blood
film (TBF) and dry blood spot (DBS) for real time poly-
merase chain reaction (qPCR) were also obtained. Night
blood samples (10:00 pm to 12.30 am) was collected from
FTS positive individuals for microscopy to detect W. ban-
crofti microfilariae, and for qPCR.
Circulating filarial antigen test with FTS
Antigen testing was performed with FTS according to the
manufacturer’s instructions. In brief, 75 μL of finger prick
blood collected from eligible participants using non-
heparinized microcapillary tubes (soda lime glass,
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Modulohm A/S Herlev, Denmark) was tested using FTS
and the test was allowed to run for 10min before being
read. The result was recorded on the data record sheet. In-
dividuals who tested either negative or positive on the FTS
were informed of the result and those who were positive
asked to return at night between 10:00 PM – 12:30 AM to
have additional blood taken for microscopic evaluation of
W. bancroftimf. It was necessary to have the blood taken at
night due to the nocturnal periodicity of W. bancrofti mf in
the blood. Quality controls for the FTS strip were con-
ducted daily before the exercise, using positive and negative
controls from the manufacturer, to ascertain standards and
kits performance throughout the study.
TBF for microscopy
Standardized 50 μL of blood was collected with a non-
heparinized microcapillary tube to identify mf of W.
bancrofti (night blood of FTS positive individuals, be-
tween 10:00 pm to 12.30 am) or mf of L. loa (day blood,
8 am to 4 pm). In brief, the collected 50 μL of blood was
placed on the centre of a clean slide, and spread repeat-
edly in a circular area of about 1.5 cm using the microca-
pillary tube. They were air dried and packaged for
staining at the base. All blood smears were stained with
10% Giemsa within 24 h. The stained smears were exam-
ined using a light microscope at 10X objective lens (or
using 40X objectives lens), for blood dwelling mf. Any
mf present were identified based on the the size and
presence or absence of a sheath, quantified and
recorded.
Whatman dry blood spot (DBS)
For each participant, 6 spots of 50 μL of blood were
loaded onto Whatman filter paper (GE Healthcare UK
Ltd., Little Chalfont, United Kingdom.) to prepare dry
blood spots (DBS) for analysis by qPCR. After drying,
DBS were kept separately in individual plastic bags at
ambient temperatures and was later stored at − 80 °C
until processed. Given the diurnal periodicity of L. loa
mf, sampling was performed between 10:00 AM and 4:
00 PM. DBS were also collected for all individuals who
were FTS positive during night blood sample collection
as described above.
Detection of filarial DNA in DBS by qPCR
DNA was extracted from the DBS, using the QIAGEN
DNeasy kit (QIAGEN, Valencia, CA) following the man-
ufacturer’s instructions. Briefly, one DBS of a participant
was cut out and placed in a 2 ml microtube, covered
with 270 μL of ATL buffer, incubated at 85 °C for 10 mi-
nutes, then at 56 °C for 1 hour after addition of 30 μL of
proteinase K. Addition of 300 μL of Al buffer to the
digested suspension brought up the lysate volume to a
total of 600 μL. From this step, the lysates were heat-
treated (100 °C), prior to the DNA purification, to de-
nature the genomic DNA to make the DNA target se-
quence more accessible to the primers. A volume of
ethanol equivalent to half the volume of lysate sample
was added before loading the mixture onto a DNeasy
spin column. Depending on the volume loaded, add-
itional centrifugations were performed to pass all the so-
lution through the column. After washing, (twice with
AW1 buffer, once with AW2 buffer), purified DNA was
eluted in 200 μL of AE buffer. The qPCR assays for W.
bancrofti were performed using 2 μL of DNA and the W.
bancrofti-specific long DNA repeat (LDR) primers as de-
scribed by Rao et al. in 2006 [18]. For the detection of
W. bancrofti the “long DNA repeat” (LDR) was used as a
target. The nucleotide sequences for the forward and re-
verse primers were LDR 1, 5′ ATTTTGATCATCTGGG
AAGGTTAATA 3′ and LDR 2, CGACTGTCTAATCC
Fig. 1 Map of the study area
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ATTCAGAGTGA3 and the sequence for the probe was
/56FAM/ATCTGCCCA/ZEN/TAGAAATAAC-
TACGGTGGAT CTCTG/3IABkFQ. All assays were
performed in duplicate using kappa probes master mix
kit (Kappa Biosystems, Wilmington, MA) with 20 pmol
of each primer (LDR1 and LDR2) and 6 pmol of LDR
probe per well in the final volume of 20 μL and the fast
PCR programmed automatically (95 °C temperature 40
cycles for 20 s, 60 °C for 1 s and 72 °C for 20 s) in a Step-
One-Plus PCR system (Applied Biosystems, Foster City).
The primers for L. loa PCR were LLMF72,
5’CGGAAGACTCAACGTCAGAAATCA3’ and
5’AGGAACGCTGATGGTGATGT3 and for the probe
was /56FAM/CCAACAGCC/Zen/TGCTTT/31ABkFQ.
qPCR were performed to identify DNA from L.loa mf as
described by Fink et al. [19]. These entire tests were per-
formed with 1 μL of extracted DNA (representing
0.1427 μL of whole blood).
Data management
Data generated either in the field or laboratory were col-
lected using smart phones and uploaded to a center
Fig. 2 The algorithm of the study design
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server coded with a password at the end of each day, to
prevent accidents or the phones getting bad. The data
were compiled and managed using Epi Info version 7.2
(Center for Disease Control and Prevention, Atlanta,
GA) and Microsoft Excel 2013. It was checked for miss-
ing values and redundancy. All missing values were reg-
istered as missing.
After cleaning, the data was re- uploaded to the main
server and hard copies in DVDs were also made. All
hardware and software carrying the research data can
only be accessed by the research team. Security pass-
word and server cupboard had been set up to protect
the data at the University of Buea/REFOTDE, Buea,
Cameroon.
Data analysis
Data were analyzed using the IBM SPSS Statistics (version
20.0, IBM, Armonk, NY, US). Some descriptive graphs
were drawn with MS Excel 2010 and Thematic analysis
were performed using the ArcGIS software (version 10.2,
ESRI Inc. Redlands, CA, US), to draw the LF map in the
31 health districts and other maps in the analysis (Using
GPS coordinates from each study community). The differ-
ences across age and gender were tested using fishers sta-
tistics and the 95% confidence interval (CI) computed.
Chi-square, Mann-Whitney and Kruskal-Wallis tests were
also used to compare LF and L. Loa prevalence level, the
Geometric mean index of infection between regions and
HDs, sex and age groups respectively. To assess the rela-
tionship between FTS positivity and L. loa Mf loads, the
geometric mean intensity (GMI) of Mf counts was calcu-
lated as follows: GMI = (∑log(x + 1)/n),Where X = the
number of Mf per ml of blood in Mf positive individuals,
n = the number of mf positive individuals. Spearman rho
correlation analysis was carried out between FTS positivity
rate and TBF data (L.loa Mf load) at the regional level to
find out if there was any relationship. Odds ratios were
calculated to quantify the risk of an individual harboring
L. loa Mf and testing positive to FTS compared to the risk
for an amicrofilaraemic individual. The value was used to
quantify the risk or the relation established by the correl-
ation statistics. Logistic regression analysis was used to de-
termine the predictors of FTS positivity. Gender, sex and
quantity of L. loa Mf load were cross tabulated with FTS
positivity.
The base map of the global administrative areas was
downloaded from the Natural Earth (https://www.natur-
alearthdata.com/) [20]. All maps were produced using
ArcGIS Desktop v10.5 (Environmental Systems Research
Institute Inc., Redlands CA, USA).
Ethical consideration
Ethical approval for this work was obtained from the
Cameroon National ethics committee (CNEC) number
2015/09/640/CE/CNERSH/SP of 16th September 2015.
The Administrative approval number D112-244NS/
MINSANTE/SG/DLMEP/SDL/PMDTN/PNLO of 11th
august 2016, was granted by the Ministry of Public
Health of Cameroon. The investigators ensured that this
study was carried out according to the current revision
of the Helsinki Declaration and Good Clinical Practices
regulations and guidelines from the International Con-
ference of Harmonization (ICH-GCP). Moreover, the in-
vestigators ensured that all protocol activities were
guided by the ethical principles of the Belmont Report,
45 CFR 46, and all its subsections (A, B, C and D). All
ethical issues like; handling of withdrawals, benefits and
risks, community participant risk with finger prick, bio-
hazard risk to field technicians, risk associated partici-
pant confidentiality and test results, reporting adverse
events and unanticipated problems, confidentiality, etc.,
as stipulated in the study protocol were strictly observed.
The purpose of the study was explained to the commu-
nity leaders and the study participants in their local lan-
guages at the time of recruitment. Individual informed
written consent was obtained from each participant. If a
participant was less than 21 years old (the age of major-
ity in Cameroon), written assent and permission were
obtained from the study participant and a legal guardian
respectively. The data was analyzed and reported to ex-
clude any directly identifiable information in order to
maintain the anonymity of the participants.
Clinical examination
Trained medical personnel recruited for this study, ex-
amined all the participants for lymphedema. All males
were examined for signs of the limb lymphedema and
hydrocele and female for limb lymphedema. The lymph-
edema cases also underwent night blood collection for




In all, 14,446 participants took part in this survey and
underwent the FTS test. Of these, 49.99% (7221/14446)
were males with a mean age of 31.8 ± 19.8 years and
50.01% (7225/14,446) were females, with a mean age of
32.1 ± 20.1 years. 4151 (28.7%) persons tested were less
than or equal to 15 years and 10,295 (71.3%) persons
tested were > 15 years (Supplementary material Table S1,
Supplementary material Fig. S3).
Prevalence of positive FTS
Out of a total of 14,446 individuals screened, 233 tested
positive with the FTS (Table 1). The overall prevalence
of positive FTS was 1.6% (233/14446), ranging from
0.0% in Abo and Bonassama HDs (Littoral Region) to
Beng et al. BMC Infectious Diseases          (2020) 20:284 Page 5 of 11
8.2% in Ayos HD (Center Region) (Fig. 3 and Supple-
mentary material Table S1). Among the 31 HDs sur-
veyed, 18 HDs had a prevalence of FTS positive rates
equaled to or greater than 1% (Supplementary material
Table S3). The males had a significantly higher FTS
positivity rate of 2.0% (141/7221) compared to the fe-
males 1.3% (92/7225) (Fischer’s statistics, p < 0.05). The
FTS positivity between the age groups was also statisti-
cally significant, higher in adults (15 years and above)
with 2.1% (218/10295) compared to 0.4% (15/4151) in
children (< 15 years) (Supplementary material Table S2).
In the Center Region, out of the 4475 participants that
took part in the study, 2.4% (109/4475) were FTS posi-
tive (Fig. 3, Supplementary material Table S7). The
prevalence in this region ranged from 0.5% (2/422) in
Ngog Mapubi HD to 8.2% (37/452) in Ayos HD. The
prevalence was higher in males 2.9% (62/2158), than in
females 2.0% (47/2317), but the difference was not sig-
nificant (p < 0.066). There was a significantly more posi-
tive FTS strips in adults 3.0% (101/3312) compared to
children 0.7% (8/1163) (p < 0.001). (Supplementary ma-
terial Table S3).
In the East region, a total of 6444 participants took part
in the study with an overall prevalence of 1.4% (87/6444).
The prevalence ranged from 0.2% (1/534) in Garoua Bou-
laye to 2.5% (12/481) in Lomie (Supplementary material
Table S3). The 1.8% (12/481) prevalence among adults was
significantly higher when compared to 0.3% (6/2005) in
Children (p < 0.001). The distribution in females was lower
than that of males, 1.1% (34/3147) and 1.6% (53/3297) re-
spectively (p < 0.067) but not statistically significant.
A total of 1789 participated in the Littoral, with a
general prevalence of 0.30% (5/1789), the FTS positiv-
ity ranged from 0.00% in Abo and Bonassama to 0.8%
(3/397) in Dibombari. Here adults (> 15 years) were
more FTS positive than children (< 15 years), with
0.40% (5/1261) and 0.00% (0/528) respectively but the
difference was not significant (p < 0.334). Though not
significant, males were more positive 0.40% (3/853)
than females 0.20% (2/936) (p < 0.674) (Supplementary
material Table S3).
In the South Region, a total of 1738 took part in the
study recording a prevalence of 1.80% (32/1738). FTS
positivity ranged from 0.60% (3/470) in Kribi to 2.7% (7/
264) in Lolodorf. Males were more positive to FTS than
females with 2.50% (23/913) and 1.10% (9/825) respect-
ively (p < 0.031). Children were significantly less positive
0.20% (1/455) compared to adults 2.40% (31/1283) (p <
0.001) (Supplementary material Table S3).
Prevalence of lymphedema
A total of one hundred and sixty three (163) lymph-
edema cases were diagnosed in the entire study popula-
tion, giving a prevalence rate of 1.14% (Supplementary
material Table S1 and Figure S4). None of them tested
positive with FTS for W. bancrofti antigen. Mbang
health district in the East region had the highest number
of lymphedema cases 36/503 (7.2%) followed by Ayos in
the Center region 20/452 (4.4%). Both males 1,1% (82/
7221) and females 1.1% (81/7225) were affected almost
equally with lymphedema.
L. loa mf load in day thick blood films (TBF)
L loa mf prevalence for the 31 health districts is shown
on Supplementary material Tables 1 & 8. The overall
prevalence of L loa mf from diurnal blood was 12.5%
(1805/14442). The prevalence ranged from 2.7% (50/
1789) in the Littoral to 16.6% (745/4475) in the Center
region (Supplementary material Table S8). A high mf
prevalence was also recorded in the East region 12.3%
(793/6442). The prevalence among the males of 14.8%
(1071/7221) was significantly higher than that in females
of 10.2% (734/7225) (p < 0.001) (Supplementary material
Table S2). Between the two age groups, adults with
15.8% (1624/10295) were significantly more infected
than children with 4.4% (181/4151) (p < 0.001). The the-
matic map showing L loa mf distribution across the 31
health districts is shown on Fig. 4.
Microfilaremia in FTS-positive individuals
We had 233 participants that were FTS positive. Micro-
scopic results were available for all 233 for day time TBF
























EAST 6444 1.4 87 61 (70.1%) 621.3 68 44 (64.70%) 61
CENTER 4475 2.4 109 65 (59.60%) 210 97 50 (51.50%) 18.9
LITTORAL 1789 0.3 5 1 (20.0%) 5.9 2 0 (0.0%) 0
SOUTH 1738 1.8 32 20 (62.5%) 344.3 21 15 (71.4%) 44.6
TOTAL 14,446 1.6 233 147 63.1% 311 188 109 58% 30.9
* + ve indicates positive, GMI geometric mean intensity, Prev prevalence, N number
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and just 188 for night time TBF (Table 1). No W. ban-
crofti mf was found on any of these slides (day or night
TBF). But, L. loa mf were present in 147/233 (63.1%)
day blood TBF and in 109/188 (58%) night blood TBF
(Supplementary material Table S9). The total mean mf
load of L. loa (mf/ml) was 11,343 during the day and
2402 at night. The average L. loa mf GMI was 311 mf/
ml during the day and 30.9 mf/ml during the night.
Correlation between positivity of FTS and prevalence of L.
loa
There was a positive correlation between the propor-
tion of positive FTS and the prevalence of L. loa mf
(Supplementary material Figure S5 and S7). In FTS
positive individuals across the four regions, FTS posi-
tivity was significantly related to L loa mf load (p <
0.001) (Supplementary material Table S6), as the
Fig. 3 FTS Positivity across the different communities
Fig. 4 Distribution of positivity of Loa loa Mf load from TBF
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amount of L loa mf load increased, the probability of
being FTS positive also increased, indicating that har-
boring L loa in the blood was a good predictor for
having a positive FTS results.
The odd ratios of a person in any of the four regions
with high L loa mf load of 8001–20,000 mf/ml being de-
tected CFA positive by FTS was 53.2 times (OR = 53.2;
95% CI: 35.2–80.4; p < 0.001), compared to an individual
in these regions with lower L loa mf load of 1–8000 mf/
ml whose odds ratio to be detected CFA positive by FTS
is just 6.1 (OR = 6.1; 95% CI: 4.4–8.6; p < 0.001). The OR
becomes extremely high when mf load was > 30,000 mf/
ml (OR = 151.9; 95% CI: 85.4–270.2; p < 0.001) (Supple-
mentary material Table S4).
The logistic model also showed that gender is not
associated with FTS positivity and L. loa prevalence
(p < 0.076) but there was a contrast across age groups,
adults had a significant risk of being FTS positive
with high L. loa loads within these four regions with
an OR of 3.395 times more than children (OR =
3.395; 95% CI: 1.942–5.935; p < 0.0001) (Supplemen-
tary material Table S10).
In Supplementary material Figure S6 a plot of
positive FTS and L loa, showed that every increase
in L loa Mf prevalence is followed by an increased
in FTS positivity. The concordance between FTS
positivity and that of Thick blood film (TBF) preva-
lence of L. loa in the surveyed Communities is in
shown in Fig. 5.
Molecular analysis by qPCR
The detection of W. bancrofti DNA by qPCR was done
for 182 of the 229 night blood DBS collected from the
FTS positive individuals. All tested negative for LDR
DNA sequence, specific to W. bancrofti. However, 104
of the 182 samples (57.1%) were positive for L. loa spe-
cific LLMF72 DNA sequence (Table 2 and Supplemen-
tary material Table S11).
There was no significant difference between the qPCR
results and those obtained from microscopy (Wilcoxon
p value p < 0.999). The qPCR and microscopy results
were plotted to depict how these tests performed in each
HD with Supplementary material Figure S8.
Discussion
The FTS is the current generation filarial antigen test
that was developed to improve on the ICT Card test for
mapping of LF. Laboratory and field evaluation of the
FTS carried out in areas with high residual LF endem-
icity after multiple MDA rounds, showed that FTS had
significant technical and practical advantages over the
ICT [21].
The prevalence of FTS positivity in the study area was
1.6%. This value is lower compared to 2.9 and 3.3%, ob-
tained in other surveys in Cameroon using the ICT in
the mapping of W. bancrofti [11, 13]. However, FTS
positivity was much higher than the prevalence obtained
by other previous works 1.1 and 0.4% [14, 22, 23]. There
is concordance between FTS positivity and L. loa density
Fig. 5 Concordance between the positivity Of FTS and positivity of TBF Loa loa in the surveyed Communities
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and prevalence, which may indicates that FTS positivity
is a result of L. loa endemicity in the study area. This
may also reflect the geographical variations in the distri-
bution of L. loa.
The FTS positivity in males 2.0% (141/7221) was
higher than that for females 1.3% (92/7225) (p < 0.05),
and this trend was previously observed in similar studies
in Sri Lanka and Indonesia [21]. The results also showed
that age was significantly associated with FTS positivity
as adults turned to be more positive than children, but
there was no significant association between gender and
FTS positivity (p < 0.075). The difference in FTS positiv-
ity within age groups, 2.1% (218/10295) above 15 years
(adults) compared to 0.4% (15/4151) less than 15 years,
showed that circulating filarial antigens (CFA) was in-
creasing with age.
FTS positivity status at the district level showed
that all but 2 of the 31 HDs had FTS non-reactive
results, and 18 HDs had FTS positivity proportions
≥1%. Similar to other results observed with the ICT
[13]. It was also observed that the level of mf/ml in
blood for L loa also increased with an increase in
age which further indicates an association between
FTS positivity and L loa mf load. The results re-
vealed that the prevalence of positive FTS falls
within other reported ranges using ICT. The main
predictor of this positivity, included high L.loa mf
load in blood and to a lesser extend the age group,
which was higher in adults > 15 years. Gender was
not associated with FTS positivity but there was a
strong association with high L. loa mf load > 8000
mf/ml of blood with high odds ratio of being FTS
positives [11, 13]. Analysis with microscopy using
night blood TBF and qPCR, indicated zero presence
of W. bancrofti but a high L loa density. The ab-
sence of W. bancrofti in night blood smears and
qPCR, confirm previous findings [15, 17], that high
L loa mf was probably the cause of FTS positivity,
as earlier observed with ICT due to cross-reaction,
since FTS was developed with the same reagents as
ICT [16].
Discrepancies were noticed between FTS results with
those obtained from microscopy and qPCR respectively.
However, previous works [15] reported high L loa mf to
be associated with false positivity of the ICT test. Due to
suspicion that FTS positivity could be caused by a pos-
sible cross-reaction between L. loa and W. bancrofti in-
fection, two methods (Microscopy and qPCR),
confirmed the absence of W. bancrofti and demonstrated
the presence of L. loa. As a consequence, there was need
to assess the intensity of L loa in FTS positive
individuals.
The overall L. loa Mf prevalence was 12.5% and the
prevalence in males was higher than in females which
are in agreement with previous works [13] but lower
than recent reports [17]. This variation can be explained
by the difference in study design and also the difference
in geographical distribution of the disease. The preva-
lence in adults (> 15 years), was higher than that in chil-
dren (< 15 years) which is in agreement with studies by
Thompson et al. [24]. This can be explained by the type
of activities people in the different age groups carry out
that exposes them to the vectors of the parasite, like
farming and hunting.
The FTS identified 1.6% (233/14446) persons as posi-
tive, implying that these individuals had CFA for W.
bancrofti, however, further investigation of these FTS
positive individuals by microscopy, using their night
blood TBF, revealed that they had no mf of W. bancrofti,
but those of L. loa, which is known to be endemic in the
rain forest of Africa. This finding suggested a relation-
ship between FTS positivity and L. loa, rather than LF
infection in these districts. Results of the molecular ana-
lysis by qPCR confirmed the presence of L. loa and the
absence of W. bancofti.
Logistic regression analyses indicated an association
between FTS positivity and L. Loa mf loads. There was a
linear relationship between FTS positivity and L loa mf
load in agreement with previous reports and later dem-
onstrated with the ICT [13, 17, 23]. FTS uses the same
principal reagents as the ICT to detect W. bancrofti CFA
and hence have the same specificity [16]. A possible
Table 2 Comparing Molecular (qPCR) with Thick blood film (TBF) microscopy of FTS positive individuals




W. bancrofti N(%) Loa loa + ve N(%) W. bancrofti N(%) Loa loa + ve N(%)
EAST 64 0 44 (68) 0 43 (67.2)
CENTER 92 0 48 (52.2) 0 46 (50)
SOUTH 23 0 12 (52.2) 0 14 (60.9)
LITTORAL 3 0 0 (0) 0 0
TOTAL 182 0 104 (57.1) 0 103 (56.6)
Mc Nemar test: p- value = 0.999
*N number
Beng et al. BMC Infectious Diseases          (2020) 20:284 Page 9 of 11
explanation could be that the CFA detected by the FTS
may be produced by L. loa and other pathogenic filariae
parasites like Onchocerca volvulus, M. perstans [25], B.
malayi. Also, the ICT components are similar with those
of FTS and include monoclonal antibodies (AD12), ori-
ginally produced by immunizing mice with antigens
from the dog heartworm Dirofilaria immitis. The ability
of this antigen to bind to other filaria species have been
reported [7, 26]. Again, all levels of L loa are capable of
inducing ICT positivity [13].
Comparative analyses between the different levels of
endemicity with L. loa mf load, showed a higher risk of
being detected FTS positive in individuals with very high
loads of L loa mf. The Odds ratio in individuals with
8001–20,000 mf/ml of blood was 53.2 but as the mf load
increased the odds ratio tripled in individuals with mf
load greater than 30,000, to 151.9. This trend had earlier
been reported [14, 27], which could serve as proof of as-
sociation between FTS positivity and L. loa mf load.
Conclusion
Our findings showed that the FTS test cross reacted
with L. loa and its positivity was not associated to the
presence of W. bancrofti in this area of Cameroon. A
strong relationship was established between FTS positiv-
ity and L. loa TBF positivity. It could be concluded that
W. bancrofti is absent from the 31 health districts situ-
ated in areas endemic for L. loa in the forest zones of
Cameroon and LF MDA is therefore not necessary in
these districts.
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